Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) plus /- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.

Trapeze Phase II

doi:10.1200/jco.2010.28.15_suppl.4677

Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) plus /- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.

Trapeze Phase II

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	28
Issue number	15
DOIs	https://doi.org/10.1200/jco.2010.28.15_suppl.4677
Publication status	Published - 20 May 2010

Access to Document

10.1200/jco.2010.28.15_suppl.4677

Cite this

@article{87975958f9d34ab1a80394ae7ff835a4,

title = "Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) plus /- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.",

author = "{Trapeze Phase II} and E. Porfiri and Collins, {S. I.} and D. Barton and L. Billingham and D. McLaren and Nixon, {G. G.} and Russell, {J. M.} and C. Parker and J. Wylie and James, {N. D.}",

year = "2010",

month = may,

day = "20",

doi = "10.1200/jco.2010.28.15_suppl.4677",

language = "English",

volume = "28",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) plus /- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747. / Trapeze Phase II.
In: Journal of Clinical Oncology, Vol. 28, No. 15, 20.05.2010.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) plus /- strontium-89 (Sr89) in hormone-refractory prostate cancer patients

T2 - ISRCTN12808747.

AU - Trapeze Phase II

AU - Porfiri, E.

AU - Collins, S. I.

AU - Barton, D.

AU - Billingham, L.

AU - McLaren, D.

AU - Nixon, G. G.

AU - Russell, J. M.

AU - Parker, C.

AU - Wylie, J.

AU - James, N. D.

PY - 2010/5/20

Y1 - 2010/5/20

U2 - 10.1200/jco.2010.28.15_suppl.4677

DO - 10.1200/jco.2010.28.15_suppl.4677

M3 - Meeting abstract

SN - 0732-183X

VL - 28

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -